Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season
Takeyuki Goto, Naoki Kawai, Takuma Bando, Yoshio Takasaki, Shizuo Shindo, Tomonori Sato, Naoki Tani, Yong Chong, Hideyuki Ikematsu · 2024
Read Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season by Takeyuki Goto, Naoki Kawai, Takuma Bando, Yoshio Takasaki, Shizuo Shindo, Tomonori Sato, Naoki Tani, Yong Chong, Hideyuki Ikematsu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11573420.txt.
Description
A peer-reviewed research article from Europe PMC (2024). BackgroundClinical data on patients infected with influenza B Victoria (BV) after the approval of baloxavir is lacking.MethodsThis observational study of the Japanese 2023–2024 influenza season analyzed data from 25 outpatients with A(H1N1)pdm09, 36 with A(H3N2), and 65 with BV. Viral samples were collected before and after administering an antiviral (70 patients received baloxavir and 56 received a neuraminidase inhibitor), on days 1, 5, and 10.
Catalog record
| CREATOR | Takeyuki Goto, Naoki Kawai, Takuma Bando, Yoshio Takasaki, Shizuo Shindo, Tomonori Sato, Naoki Tani, Yong Chong, Hideyuki Ikematsu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |